As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become popular when used as a weight loss drug. But, experts warn there can be ...

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced ... ever conducted on the drug class – based on 2.4 million people in the US Department of Veterans ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

The Post-Bariatric Hypoglycemia market growth is driven by factors like increase in the prevalence of Post-Bariatric ...

Global Partners LP (NYSE:GLP) Q1 2024 Earnings Call Transcript May 8, 2024 Global Partners LP misses on earnings expectations. Reported EPS is $-0.37258 EPS, expectations were $0.1. GLP isn’t ...

A step-by-step guide to help you fill out a W-4 Thanasis / Getty Images You're about to begin that much-needed, new job and your employer hands you an IRS Form W-4 to fill out and submit to them ...